引用本文:黄宝乐,吴 峰,岳 悦,郑桂玲.甲亢患者血清miR-133a水平变化与甲状腺激素及脂质代谢的关联性研究[J].中国临床新医学,2024,17(3):307-311.
【打印本页】   【下载PDF全文】   查看/发表评论  【EndNote】   【RefMan】   【BibTex】
←前一篇|后一篇→ 过刊浏览    高级检索
本文已被:浏览 444次   下载 431 本文二维码信息
码上扫一扫!
分享到: 微信 更多
甲亢患者血清miR-133a水平变化与甲状腺激素及脂质代谢的关联性研究
黄宝乐,吴 峰,岳 悦,郑桂玲
中国人民解放军联勤保障部队第九八三医院内分泌科,天津 300000
摘要:
[摘要] 目的 探讨甲亢患者血清miR-133a水平变化与甲状腺激素及脂质代谢的关联性。方法 招募2020年10月至2022年8月中国人民解放军联勤保障部队第九八三医院收治的新发显性甲亢患者100例(甲亢组),其中28例患者接受标准甲巯咪唑治疗;另选择同期健康体检者100名作为对照组。收集研究对象的性别、年龄、甲状腺激素、肝功能及其他生化指标等临床资料。采用实时荧光定量聚合酶链式反应(PCR)法检测血清miR-133a水平,分析其与甲状腺激素及脂质代谢水平的相关性。结果 与对照组相比,甲亢组游离甲状腺素(FT4)、游离三碘甲状腺原氨酸(FT3)、促甲状腺激素受体抗体(TRAb)、舒张压、丙氨酸转氨酶(ALT)、总胆红素(TBIL)和直接胆红素(DBIL)水平较高,体质量指数(BMI)、腰围、总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)、促甲状腺激素(TSH)水平较低,差异有统计学意义(P<0.05)。甲亢组血清miR-133a水平显著低于对照组(Z=9.796,P<0.001)。甲亢组血清miR-133a水平与ALT、FT3、FT4水平呈负相关(P<0.05),与TC、LDL-C和TSH水平呈正相关(P<0.05)。在接受甲巯咪唑治疗后,甲亢患者FT3和FT4水平显著降低(P<0.05),TC、LDL-C、TSH及血清miR-133a水平显著升高(P<0.05)。治疗前后血清miR-133a水平变化值与FT3rs=-0.728,P<0.001)、FT4rs=-0.377,P=0.048)水平变化值呈负相关,但与TC、TG、LDL-C和TSH水平变化值相关性不显著(P>0.05)。结论 甲亢患者血清miR-133a水平下调,这可能与甲状腺激素升高导致的脂质代谢紊乱有关。
关键词:  甲状腺功能亢进  miR-133a  甲状腺激素  脂质代谢紊乱
DOI:10.3969/j.issn.1674-3806.2024.03.12
分类号:R 581.1
基金项目:天津市卫生计生委科技基金项目(编号:2020KZ122)
A study on the correlation of changes in serum miR-133a levels with thyroid hormone and lipid metabolism in hyperthyroidism patients
HUANG Baole, WU Feng, YUE Yue, ZHENG Guiling
Department of Endocrinology, the 983rd Hospital of the Chinese People′s Liberation Army Joint Logistics Support Force, Tianjin 300000, China
Abstract:
[Abstract] Objective To explore the correlation of changes in serum miR-133a levels with thyroid hormone and lipid metabolism in hyperthyroidism patients. Methods A total of 100 patients with new onset of dominant hyperthyroidism who were admitted to the 983rd Hospital of the Chinese People′s Liberation Army Joint Logistics Support Force from October 2020 to August 2022 were recruited as the hyperthyroidism group, of whom 28 patients received standard methimazole treatment. Other 100 healthy individuals who underwent physical examination during the same period were selected as the control group. The clinical data such as gender, age, thyroid hormone, liver function and biochemical indicators of the research subjects were collected. The serum miR-133a level was detected by using real-time fluorescence quantitative polymerase chain reaction(PCR), and the correlation of serum miR-133a level with thyroid hormone and lipid metabolism levels was analyzed. Results Compared with those in the control group, the levels of free thyroxine(FT4), free triiodothyronine(FT3), thyroid-stimulating hormone receptor antibody(TRAb), diastolic blood pressure, alanine aminotransferase(ALT), total bilirubin(TBIL) and direct bilirubin(DBIL) in the hyperthyroidism group were increased, while the levels of body mass index(BMI), waist circumference, total cholesterol(TC), triglyceride(TG), low-density lipoprotein cholesterol(LDL-C) and thyroid-stimulating hormone(TSH) in the hyperthyroidism group were decreased, and the differences were statistically significant(P<0.05). The serum miR-133a level in the hyperthyroidism group was significantly lower than that in the control group(Z=9.796, P<0.001). In the hyperthyroidism group, the serum miR-133a level was negatively correlated with ALT, FT3 and FT4 levels(P<0.05), and was positively correlated with TC, LDL-C and TSH levels(P<0.05). After receiving treatment with methimazole, the hyperthyroidism patients had significantly decreased FT3 and FT4 levels(P<0.05), and significantly increased TC, LDL-C, TSH and serum miR-133a levels(P<0.05). The changes in serum miR-133a levels before and after treatment were negatively correlated with the changes in FT3(rs=-0.728, P<0.001) and FT4 levels(rs=-0.377, P=0.048), but were not significantly correlated with the changes in TC, TG, LDL-C and TSH levels(P>0.05). Conclusion The serum miR-133a levels in hyperthyroidism patients are down-regulated, which may be related to the lipid metabolism disorders caused by elevated thyroid hormone.
Key words:  Hyperthyroidism  miR-133a  Thyroid hormone(TH)  Lipid metabolism disorder